Link to home
Start Free TrialLog in
Avatar of spectrumsofttech
spectrumsofttechFlag for India

asked on

Javascript for search and extract XML

Need Help very Badly..

I have attached a xml code.. What I am trying to do is


1)Extract specific tag datas (only data no <tag>)

2)script needed to be able to extract multiple tag data(it will be needed to extract multiple data from one single file)

3)What I am trying to extract is  paragraph session in xml file which can be uniquely identified by 34073-7 (which is under the tag code).. Display Name "Drug interaction". Also code "42232-9" displayName="PRECAUTIONS SECTION"(item and paragraph)

4)This code will be used in mirth not in any web pages etc

As I am really bad in java scripting any help will be appreciated
   
<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="93803c4f-788e-43ae-a68e-ded89f8c6d2c"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>Robinul and Robinul Forte</title>
   <effectiveTime value="20100101"/>
   <setId root="bd65ee5e-2000-423c-b0a6-72eb213455c4"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="802728477" root="1.3.6.1.4.1.519.1"/>
            <name>Shionogi Pharma, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="db0b287a-1f34-407d-bf01-1f7bc9b7d198"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL LISTING DATA ELEMENTS SECTION"/>
               <effectiveTime value="20100625"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="59630-200" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Robinul</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Glycopyrrolate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="1" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="V92SO9WP2I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Glycopyrrolate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="V92SO9WP2I" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>glycopyrrolate</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L11K75P92J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>anhydrous dibasic calcium phosphate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="J2B2A4N98G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>lactose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>magnesium stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>povidone</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="59630-200-10" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA012827" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19610328"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48676" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CIII"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText>ROUND</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="8" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">HPC;200</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="59630-205" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Robinul Forte</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Glycopyrrolate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="2" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="V92SO9WP2I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Glycopyrrolate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="V92SO9WP2I" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>glycopyrrolate</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L11K75P92J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>anhydrous dibasic calcium phosphate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="J2B2A4N98G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>lactose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>magnesium stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>povidone</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="59630-205-10" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA012827" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19610328"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48676" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CIII"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText>ROUND</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="10" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">HORIZON;205</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="47a9a715-c560-451c-9573-045a71c5b15b"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title mediaType="text/x-hl7-title+xml"/>
               <text>
                  <paragraph>Sciele<br/>Atlanta, GA 30328<br/>
                     <content styleCode="bold">Robinul<sup>®</sup> and Robinul<sup>®</sup> Forte </content>
                     <br/>(Glycopyrrolate Tablets, USP)<br/>
                     <content styleCode="bold">Rx Only</content>
                     <br/>Code: 883C00          Rev. 04/10<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20100625"/>
            </section>
         </component>
         <component>
            <section>
               <id root="ef555bb2-1a79-4350-8041-7197f91c9586"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
               <text>
                  <paragraph>Robinul<sup>®</sup> and Robinul<sup>®</sup> Forte tablets contain the synthetic anticholinergic, glycopyrrolate.  Glycopyrrolate is a quaternary ammonium compound with the following chemical name: 3-[(cyclopentylhydroxyacetyl)oxy]-1,1-dimethylpyrrolidinium bromide.<br/> <br/>
                     <content styleCode="bold">Robinul</content> tablets are scored, compressed white tablets engraved HPC 200.  Each tablet contains:<br/>Glycopyrrolate, USP………..1 mg<br/> <br/>
                     <content styleCode="bold">Robinul Forte </content>tablets are scored, compressed white tablets engraved HORIZON 205.  Each tablet contains:<br/>Glycopyrrolate, USP……….2 mg<br/> <br/>
                     <content styleCode="bold">Inactive Ingredients</content>: Dibasic Calcium Phosphate, Lactose, Magnesium Stearate, Povidone, Sodium Starch Glycolate<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20100625"/>
            </section>
         </component>
         <component>
            <section>
               <id root="6ff1ff49-a087-4a72-ad9e-322adb61a1f7"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title mediaType="text/x-hl7-title+xml">ACTIONS</title>
               <text>
                  <paragraph>Glycopyrrolate, like other anticholinergic (antimuscarinic) agents, inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine by lack cholinergic innervation.  These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sino-atrial node, the atrioventricular node, exocrine glands, and, to a limited degree, in the autonomic ganglia.  Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions. <br/> <br/>Glycopyrrolate antagonizes muscarinic symptoms (e.g., bronchorrhea, bronchospasm, bradycardia, and intestinal hypermotility) induced by cholinergic drugs such as the anticholinesterases.<br/> <br/>The highly polar quaternary ammonium group of glycopyrrolate limits its passage across lipid membranes, such as the blood-brain barrier, in contrast to atropine sulfate and scopolamine hydrobromide, which are non-polar tertiary amines which penetrate lipid barriers easily.<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20100625"/>
            </section>
         </component>
         <component>
            <section>
               <id root="0361fe2a-1ba2-4e0f-a7d2-b2e365046f90"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title mediaType="text/x-hl7-title+xml">INDICATIONS</title>
               <text>
                  <paragraph>For use as adjunctive therapy in the treatment of peptic ulcer.</paragraph>
               </text>
               <effectiveTime value="20100625"/>
            </section>
         </component>
         <component>
            <section>
               <id root="a9cf9dcf-e00c-44cd-a028-0c8cb972ea7b"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis.  Robinul (glycopyrrolate) tablets are contraindicated in those patients with a hypersensitivity to glycopyrrolate.</paragraph>
               </text>
               <effectiveTime value="20100625"/>
            </section>
         </component>
         <component>
            <section>
               <id root="b5d0b99e-af71-4105-b841-e3290620c658"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">WARNINGS</title>
               <text>
                  <paragraph>In the presence of a high environmental temperature, heal prostration (fever and heat stroke due to decreased sweating) can occur with the use of Robinul.<br/> <br/>Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy.  In this instance treatment with this drug would be inappropriate and possibly harmful.<br/> <br/>Robinul (glycopyrrolate) may produce drowsiness or blurred vision.  In this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery, or performing hazardous work while taking this drug. <br/> <br/>Theoretically, with overdosage, a curare-like action may occur, i.e., neuro-muscular blockade leading to muscular weakness and possible paralysis. <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20100625"/>
               <component>
                  <section>
                     <id root="46751d4d-5a10-4943-80a0-4209a21582b9"/>
                     <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">Pregnancy</title>
                     <text>
                        <paragraph>The safety of this drug during pregnancy has not been established.  The use of any drug during pregnancy requires that the potential benefits of the drug be weighed against possible hazards to mother and child.  Reproduction studies in rats revealed no teratogenic effects from glycopyrrolate; however, the potent anticholinergic action of this agent resulted in diminished rates of conception and of survival at weaning, in a dose-related manner.  Other studies in dogs suggest that this may be due to diminished seminal secretion which is evident at high doses of glycopyrrolate.  Information on possible adverse effects in the pregnant female is limited to uncontrolled data derived from marketing experience.  Such experience has revealed no reports of teratogenic or other fetus-damaging potential.  No controlled studies to establish the safety of the drug in pregnancy have been performed.</paragraph>
                     </text>
                     <effectiveTime value="20100625"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="4621256b-ba26-4e92-a458-7c934272aac9"/>
                     <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">Nursing Mothers</title>
                     <text>
                        <paragraph>It is not know whether this drug is excreted in human milk.  As a general rule, nursing should not be undertaken while a patient is on a drug since many drugs are excreted in human milk.</paragraph>
                     </text>
                     <effectiveTime value="20100625"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="313f2e24-10ec-4b92-a28a-527aff42ab8e"/>
                     <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">Pediatric Use</title>
                     <text>
                        <paragraph>Since there is no adequate experience in pediatric patients who have received this drug, safety and efficacy in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20100625"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="89190c26-47b8-4f69-b5a8-36e5f653d18c"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
               <text>
                  <paragraph>Use Robinul with caution in the elderly and in all patients with:<br/> <br/>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Autonomic neuropathy.</item>
                     <item>Hepatic or renal disease.</item>
                     <item>Ulcerative colitis - large doses may suppress intestinal motility to the point of producing a paralytic ileus and for this reason may precipitate or aggravate the "toxic megacolon," a serious complication of the disease.</item>
                     <item>Hyperthyroidism, coronary heart disease, congestive heart failure, cardiac tachyarrhythmias, tachycardia, hypertension and prostatic hypertrophy.</item>
                     <item>Hiatal hernia associated with reflux esophagitis, since anticholinergic drugs may aggravate this condition. </item>
                  </list>
                  <paragraph>
                     <br/> <br/> <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20100625"/>
            </section>
         </component>
         <component>
            <section>
               <id root="ad9f6c4c-ea53-4b61-adf8-a2548d2086b4"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Anticholinergics produce certain effects, most of which are extensions of their fundamental pharmacological actions.  Adverse reactions to anticholinergics in general may include xerostomia; decreased sweating; urinary hesitancy and retention; blurred vision; tachycardia; palpitations; dilation of the pupil; cycloplegia; increased ocular tension; loss of taste; headaches; nervousness; mental confusion; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; constipation; bloated feeling; impotence; suppression of lactation; severe allergic reaction or drug idiosyncrasies including anaphylaxis, urticaria and other dermal manifestations.<br/> <br/>Robinul (glycopyrrolate) is chemically a quaternary ammonium compound; hence, its passage across lipid membranes, such as the blood-brain barrier, is limited in contrast to atropine sulfate and scopolamine hydrobromide.  For this reason the occurrence of CNS related side effects is lower, in comparison to their incidence following administration of anticholinergics which are chemically tertiary amines that can cross this barrier readily.<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20100625"/>
            </section>
         </component>
         <component>
            <section>
               <id root="583f2615-2026-4c12-b6b8-31c4e529f4e4"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title mediaType="text/x-hl7-title+xml">OVERDOSAGE</title>
               <text>
                  <paragraph>The symptoms of overdosage of glycopyrrolate are peripheral in nature rather than central.<br/> <br/>
                  </paragraph>
                  <list listType="ordered" styleCode="Arabic">
                     <item>To guard against further absorption of the drug - use gastric lavage, cathartics, and/or enemas.</item>
                     <item>To combat peripheral anticholinergic effects (residual mydriasis, dry mouth, etc.) - utilize a quaternary ammonium anticholinesterase, such as neostigmine methylsulfate.</item>
                     <item>To combat hypotension - use pressor amines (norepinephrine, metaraminol) i.v.; and supportive care.</item>
                     <item>To combat respiratory depression - administer oxygen; utilize a respiratory stimulant such as Dopram® i.v.; artificial respiration.</item>
                  </list>
                  <paragraph/>
               </text>
               <effectiveTime value="20100625"/>
            </section>
         </component>
         <component>
            <section>
               <id root="81f65aa5-b542-4b11-bfdc-cc2c9d7a7e87"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>
                     <content styleCode="italics">The dosage of Robinul<sup>®</sup> or Robinul<sup>®</sup> Forte should be adjusted to the needs of the individual patient to assure symptomatic control with a minimum of adverse reactions. The presently recommended maximum daily dosage of glycopyrrolate is 8 mg.</content>
                     <br/>
                     <content styleCode="italics"/> <br/>
                     <content styleCode="bold">Robinul</content> (glycopyrrolate, 1 mg) tablets.  The recommended initial dosage of Robinul for adults is one tablet three times daily (in the morning, early afternoon, and at bedtime).  Some patients may require two tablets at bedtime to assure overnight control of symptoms.  For maintenance, a dosage of one tablet twice a day is frequently adequate.<br/> <br/>
                     <content styleCode="bold">Robinul Forte</content> (glycopyrrolate, 2 mg) tablets.  The recommended dosage of Robinul Forte for adults is one tablet two or three times daily at equally spaced intervals.<br/> <br/>Robinul tablets are not recommended for use in pediatric patients under the age of 12 years.<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20100625"/>
            </section>
         </component>
         <component>
            <section>
               <id root="48b3f6c4-d211-4679-abf0-5dc6fcb442ea"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">DRUG INTERACTIONS</title>
               <text>
                  <paragraph>There are no known drug interactions.</paragraph>
               </text>
               <effectiveTime value="20100625"/>
            </section>
         </component>
         <component>
            <section>
               <id root="8a8ca414-249c-40ac-b15a-138ea3e54f77"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
               <text>
                  <paragraph>Robinul<sup>®</sup> (glycopyrrolate, 1 mg) tablets in bottles of 100 (NDC 59630-200-10). <br/> <br/>Robinul<sup>®</sup> Forte (glycopyrrolate, 2 mg) tablets in bottles of 100 (NDC 59630-205-10).<br/> <br/>
                     <content styleCode="bold">Store at controlled room temperature, 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C-30°C (59°F-86°F) [See USP Controlled Room Temperature].  Keep out of reach of children.</content>
                     <br/>
                     <content styleCode="bold"/> <br/>
                     <content styleCode="bold">Dispense in tight container.</content>
                     <br/>
                     <content styleCode="bold"/> <br/>
                     <content styleCode="bold">Rx only</content>
                     <br/> <br/>ROB-PI-2<br/>Rev. 04/10                 Code 883C00                Printed in USA<br/> <br/>Manufactured by:<br/>
                     <content styleCode="bold">MIKART, INC.</content>
                     <br/>Atlanta, GA 30318<br/> <br/>Manufactured for:<br/>
                     <content styleCode="bold">SHIONOGI PHARMA, INC.</content>
                     <br/>Atlanta, GA 30328<br/>
                  </paragraph>
               </text>
               <effectiveTime value="20100625"/>
            </section>
         </component>
         <component>
            <section>
               <id root="88882991-ce28-49e0-8d81-a90a0270882a"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 1 mg Bottle Label</title>
               <text>
                  <paragraph>NDC 59630-200-10<br/>100 Tablets</paragraph>
                  <paragraph>
                     <content styleCode="bold">ROBINUL<sup>®</sup>
                        <br/>(glycopyrrolate tablets, USP)<br/>1 mg</content>
                  </paragraph>
                  <paragraph>WHITE DYE-FREE</paragraph>
                  <paragraph>Manufactured for :<br/>
                     <content styleCode="bold">SHIONOGI PHARMA, INC.</content>
                     <br/>Atlanta, GA 30328    U.S. Patent No. 7,091,236</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
               </text>
               <effectiveTime value="20100625"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Principal Display Panel - 1 mg Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="robinul-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="b9e89bf3-b940-4d4d-ab1d-27f5ea28db87"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 2 mg Bottle Label</title>
               <text>
                  <paragraph>NDC 59630-205-10<br/>100 Tablets</paragraph>
                  <paragraph>
                     <content styleCode="bold">ROBINUL<sup>®</sup>
                        <br/>(glycopyrrolate <br/>tablets, USP)<br/>2 mg</content>
                  </paragraph>
                  <paragraph>WHITE DYE-FREE</paragraph>
                  <paragraph>Manufactured for :<br/>
                     <content styleCode="bold">SHIONOGI PHARMA, INC.</content>
                     <br/>Atlanta, GA 30328</paragraph>
                  <paragraph>U.S. Patent No. 7,091,236</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20100625"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Principal Display Panel - 2 mg Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="robinul-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>

Open in new window

ASKER CERTIFIED SOLUTION
Avatar of Gurvinder Pal Singh
Gurvinder Pal Singh
Flag of India image

Link to home
membership
This solution is only available to members.
To access this solution, you must be a member of Experts Exchange.
Start Free Trial
Avatar of spectrumsofttech

ASKER

How to i use xpath with javascript(as mirth support java script) for this purpose.. Please dont sugest to study a new language just to do this :-)..

Any sample/example would be appreciated.. I could use that an reference

Thanks for your reply

SOLUTION
Link to home
membership
This solution is only available to members.
To access this solution, you must be a member of Experts Exchange.
Start Free Trial
3 hours on it i am no where at a solution.. If i move forward i will end up studying XLTS.. Studying something new is exiting but i dont have time for new right now..

1) searched for a tag called paragraph it show all the paragraph tags i only need one set of paragraph, which can be identified by a different tag called code with value 34073-7.. How will i link code tag with subsquent paragraph tag.. I am stuck..

Thanks for your time..
SOLUTION
Link to home
membership
This solution is only available to members.
To access this solution, you must be a member of Experts Exchange.
Start Free Trial
Ok thanks you very much for your help... If that's not possible i could also live with a script(perl,js) that extract the corresponding paragraph with the code 34073-7,42232-9".. I could make the mirth read from a file..  
SOLUTION
Link to home
membership
This solution is only available to members.
To access this solution, you must be a member of Experts Exchange.
Start Free Trial
Hai Sorry for delay, Was on leave..

So i have attached a code which has the following part(one a protion i need to extract..

You could see every componet has a tag called code with a value attached i need to examin that value to determine to extract the below paragraph..

In the code attache its value is

                             <code codeSystem="2.16.840.1.113883.6.1" code="34073-7" displayName="DRUG INTERACTIONS SECTION"/>       


34073-7

getting this value i need to only extract the paragraphs in text tag..

                             <text>
                   <paragraph>Fentanyl is metabolized mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4); therefore potential interactions may occur when OTFC is given concurrently with agents that affect CYP3A4 activity. The concomitant use of OTFC with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazodone) or moderate CYP3A4 inhibitors (e.g., amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, and verapamil) may result in increased fentanyl plasma concentrations, potentially causing serious adverse drug effects including fatal respiratory depression. Patients receiving OTFC concomitantly with moderate or strong CYP3A4 inhibitors should be carefully monitored for an extended period of time. Dosage increase should be done conservatively.</paragraph>
                   <paragraph>Grapefruit and grapefruit juice decrease CYP3A4 activity, increasing blood concentrations of fentanyl, thus should be avoided.</paragraph>
                   <paragraph>Drugs that induce cytochrome P450 3A4 activity may have the opposite effects.</paragraph>
                   <paragraph>Concomitant use of OTFC with an MAO inhibitor, or within 14 days of discontinuation, is not recommended [<content styleCode="italics">see Warnings And Precautions (<linkHtml href="#i4i_section_id_d1a3dca8-aff3-49ca-8ece-5d3cab033de6">5.9</linkHtml>)</content>]<content styleCode="italics">.</content>
                   </paragraph>
                </text>       


That's what i trying to do.. Need any more clarification.. Really appreciate your help..

<component>
            <section ID="i4i_interactions_id_69891e95-4487-472a-ab64-45e6b5a6c61c">
               <id root="73ad92db-420c-4b08-a71d-48b5e4813ec6"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34073-7" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Fentanyl is metabolized mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4); therefore potential interactions may occur when OTFC is given concurrently with agents that affect CYP3A4 activity. The concomitant use of OTFC with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazodone) or moderate CYP3A4 inhibitors (e.g., amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, and verapamil) may result in increased fentanyl plasma concentrations, potentially causing serious adverse drug effects including fatal respiratory depression. Patients receiving OTFC concomitantly with moderate or strong CYP3A4 inhibitors should be carefully monitored for an extended period of time. Dosage increase should be done conservatively.</paragraph>
                  <paragraph>Grapefruit and grapefruit juice decrease CYP3A4 activity, increasing blood concentrations of fentanyl, thus should be avoided.</paragraph>
                  <paragraph>Drugs that induce cytochrome P450 3A4 activity may have the opposite effects.</paragraph>
                  <paragraph>Concomitant use of OTFC with an MAO inhibitor, or within 14 days of discontinuation, is not recommended [<content styleCode="italics">see Warnings And Precautions (<linkHtml href="#i4i_section_id_d1a3dca8-aff3-49ca-8ece-5d3cab033de6">5.9</linkHtml>)</content>]<content styleCode="italics">.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20091207"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Monitor patients who begin or end therapy with potent inhibitors of CYP450 3A4 for signs of opioid toxicity. (<linkHtml href="#i4i_section_id_03c0f38e-f4e2-4a23-bd84-96a34f445964">5.4</linkHtml>, <linkHtml href="#i4i_interactions_id_69891e95-4487-472a-ab64-45e6b5a6c61c">7</linkHtml>)  </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>

Open in new window

5924312e-27ac-40cc-a19a-f9a7274d.xml
Any Update ...
good